Get started
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

No trades
Buy REGN
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

REGN trade ideas

ridethepig | Regeneron Pharmaceuticals📌 REGN pipeline (with particular focus on the early stages) CEMIPLIMAB, REGN3767, REGN1979, REGN4018, REGN5458, REGN5459, REGN5678, REGN5093, REGN5713-5714-5715 and REGN-COV2 all have a lot of potential with particular focus around oncology. As can be see with GILD, the covid positioning has already moved on a lot: we are ready to play chapter II and REGN is a name worth considering for those looking to add single stock opps to their portfolio. Buyers are clearly exercising control here on the Monthly chart at $600. To the topside there is very little in-between here and $1,000 as the next big level. Thanks as usual for keeping the feedback coming 👍 or 👎
NASDAQ:REGNLong
by ridethepig
REGN Ready to Rally?I've opened a position based on a number of technical and fundamental indicators. If however, it cannot hold today's low, I'm wrong and gone. On a technical basis it has broken it's recent downtrend line. It has also risen above it's most recent high and it seems to have found support at the support area I've drawn with the blue line. Things I don't like is that it's RS line is low, according to IDB is at an RSI of 11 so not a CANSLIM style stock. It did have an earnings beat on May 6 and I look at this as an earnings follow-thru. Ideas, not investing / trading advice. From earningswhispers.com: Regeneron Pharmaceuticals Beats Regeneron Pharmaceuticals (REGN) reported 1st Quarter March 2021 earnings of $11.33 per share on revenue of $2.5 billion. The consensus earnings estimate was $9.02 per share on revenue of $2.5 billion. The Earnings Whisper number was $9.84 per share. Revenue grew 38.3% on a year-over-year basis. Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
NASDAQ:REGNLong
by jaxdog
2
REGN - Good timing for entryThis can be a good opportunity to jump in on REGN . The price performance has been declining significantly over the last months, yet the fundamental performance of REGN has proved to be resilient and pretty healthy. As the stock seems to hit a major support area , this can be the right opportunity to buy in. I am bullish on this one for the long term. I would set the stop around 440-430. Key fundamental stats: - EPS % Chg (Last Qtr): 27% - 3 Year EPS Growth Rate: 21% - Sales % Chg (Last Qtr): 30% - EPS Est % Chg (Current Yr): 43%
NASDAQ:REGNLong
by HR_D
4
Regeneron (REGN) Is an absolutely massive opportunityHi guys, hope you are well. Today we will be looking at Regeneron, hopefully at this point you understand the basics of Elliot wave and my diagram should be easily explainable. Wave 1 formed nicely with Wave 2 becoming an ending diagonal triangle in a corrective structure. The beginning of wave 3 has formed, and the structure is perfect for an investment opportunity. Usually wave 2 within a 5 wave structure is the sharper correction, and we can see this is proven within the diagram. Now, I see the stock hitting possible lows of 450-435, however as this is not certain, I will be investing at the end of this week, whatever the outcome. Wave 3 is usually the longest wave within the 5 wave structure, and considering we are currently in a correction within the 3rd wave, I couldn't think of a better, risk managed to perfection, play. ARK investment has been investing heavily into this stock over the last few months, and this is what initially brought me to the stock, and now I can see why. With the 1st wave reaching highs of 675, a current price of 470 roughly is just perfect for an entry point. I see this as being an easy 100% return stock, very likely more. This is not investment advice, please do your own due diligence. I hope this helps, please give me your opinions in the comment section
NASDAQ:REGNLong
by ASA2001
REGN trend reversal and 30% upsideRecently, NASDAQ:REGN has been in a downtrend. As supported by the technical indicators, there seems to be a potential trend reversal with a potential upside of 30% as evidenced by the oversold RSI level of <30 and a potential bullish divergence. A LONG initiated at or near $460 PS supported by near fib retracement level indicates 30% upside with the upside target of $600 and downside bearish target of $398 over the next quarter. The technicals are also supported fundamentally by strong revenue growth of 30% Y/Y and a P/E of ~15 which is abnormally low for the stock. With the strong projected growth and multiple upcoming catalysts for the stock, it poses a unique opportunity for both mid-term and long-term investors. Furthermore, analyst consensus converges to mid $700.
NASDAQ:REGNLong
by marc_cermak
2
REGN Presents a good potential long opportunity. I am fairly new to analysis so take this with a grain of salt. But I believe REGN is in a downward channel and for the past two weeks or so has been hovering around two support levels. Due to the strong fundamentals of the company, and the fact that they beat earnings and have had only positive recent news. I believe that REGN is currently at a good buy point and will start climbing upward over the next few months(assuming no market correction/crash). Stoch indicates that REGN is oversold, and is trending upwards. The MACD just turned green, and there is bullish deviation between the RSI and the price (the right side of the most recent dip is higher up on the RSI than the price. Anyway, this is just my opinion not financial advice I would be interested in hearing others perspectives.
NASDAQ:REGNLong
by zytenthecruel
REGENERON strong fundamental at discounted price!Regeneron Pharmaceuticals (NASDAQ:REGN) has had a rough three months with its share price down 8.2%. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Specifically, we decided to study Regeneron Pharmaceuticals' ROE in this article. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.
NASDAQ:REGNLong
by ShukriMahadi
4